Interestingly, nilotinib profiling by chemical proteomic methods led to the discovery that DDR1 is the highest affinity target of nilotinib in CML (Rix et al, 2007). Here, DDR1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.